1235449-52-1 Usage
Uses
Used in Oncology:
PI3Kα inhibitor 1 is used as an anticancer agent for its ability to target and inhibit the overactive PI3Kα enzyme, which is frequently implicated in the development and progression of many types of cancer. By doing so, it can help control tumor growth and potentially enhance the effectiveness of other cancer treatments.
Used in Pharmaceutical Research:
In the realm of pharmaceutical research, PI3Kα inhibitor 1 serves as a valuable tool for studying the role of PI3Kα in cellular processes and disease mechanisms. Its selective inhibition of PI3Kα makes it instrumental in understanding the enzyme's contribution to various pathophysiological conditions.
Used in Drug Development:
PI3Kα inhibitor 1 is utilized in drug development as a lead compound for creating new therapeutics targeting the PI3Kα pathway. Its chemical structure and mechanism of action provide a foundation for designing more effective and specific drugs to treat diseases where PI3Kα plays a significant role.
Used in the Treatment of Diabetes and Cardiovascular Diseases:
Given the involvement of PI3Kα in glucose metabolism and cardiovascular function, PI3Kα inhibitor 1 is explored as a potential therapeutic agent for diabetes and cardiovascular diseases. Its ability to modulate PI3Kα activity could help in managing these conditions by affecting the underlying molecular pathways.
Used in Immunology Research:
PI3Kα plays a role in immune cell function, and thus, PI3Kα inhibitor 1 is used in immunology research to study the enzyme's impact on immune responses and disorders. This can aid in developing targeted therapies for immune-related diseases by understanding how PI3Kα inhibition affects immune cell behavior.
Check Digit Verification of cas no
The CAS Registry Mumber 1235449-52-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,5,4,4 and 9 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1235449-52:
(9*1)+(8*2)+(7*3)+(6*5)+(5*4)+(4*4)+(3*9)+(2*5)+(1*2)=151
151 % 10 = 1
So 1235449-52-1 is a valid CAS Registry Number.
1235449-52-1Relevant articles and documents
COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
-
Paragraph 0087; 0113-0114; 0127, (2020/04/09)
The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.
Thiophene pyrimidines and preparation and its preparation method and application
-
, (2017/08/22)
The invention discloses a pyrantel compound and preparation, as well as a preparation method and application of the pyrantel compound and preparation, belonging to the technical field of chemical medicines and preparations thereof. According to the pyrantel compound or pharmaceutically acceptable salt thereof, HDAC (histone deacetylase)/PI3K (phosphatidylinositide 3-kinase) double-target inhibitor is used for selectively inhibiting tumor cell messenger core protein kinase target PI3K and epigenetic target HDAC which are synergized, and is capable of destroying the network of tumor cell messengers, thus exerting a great killing effect on various tumor cells. In multiple blood and entity heterogenic transplanted tumor animal models, the inhibitor can be used for intensively effectively inhibiting tumor growth and especially has a remarkable effect on various blood B-cell malignant tumors, and safety evaluation tests indicate that the inhibitor has high safety and security. The pyrantel compound and preparation can be used for effectively treating patients with later reoccurrence of lymphoma, myeloma and lymphatic leukemia or drug resistance.
